Bottom line
JDOC vs RSPH: the short answer
JDOC (JPMorgan Healthcare Leaders ETF) and RSPH (Invesco S&P 500 Equal Weight Health Care ETF) are quite different portfolios: only about 23% of their top holdings (by weight) are shared.
RSPH is cheaper at 0.4% vs 0.65% — a difference of $25 a year per $10,000 invested.
Over one year, JDOC returned +14.9% vs +9.3% for RSPH.
Updated Nov 19, 2026
JDOC vs RSPH side by side
| JDOC | RSPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | J.P. Morgan | Invesco |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.65% | 0.4% |
| Annual cost per $10k | $65 | $40 |
| 10-yr cost on $10k (prospectus) | $810 | $505 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +14.9% | +9.3% |
| 5-yr return (annualized) | — | +4.7% |
| 10-yr return (annualized) | — | +8.2% |
| Best quarter | +11.3% | +17.5% |
| Worst quarter | −11.9% | −14.3% |
| Net assets (fund) | $9.1M | $766.9M |
| Number of holdings | 61 | 63 |
| Portfolio turnover | 92% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | JDOC | RSPH | Difference |
|---|---|---|---|
| 2025 | +14.9% | +9.3% | +5.6% |
| 2024 | −0.6% | −0.8% | +0.2% |
Source: Fund prospectus bar charts
Holdings overlap
7 of JDOC's top 25 holdings also appear in RSPH's top 25.
| Holding | JDOC | RSPH |
|---|---|---|
| AbbVie, Inc. | 7.85% | 1.73% |
| Thermo Fisher Scientific, Inc. | 3.73% | 1.84% |
| Bristol-Myers Squibb Co. | 3.57% | 1.82% |
| Abbott Laboratories | 3.11% | 1.83% |
| Cencora, Inc. | 2.07% | 1.71% |
| IQVIA Holdings, Inc. | 1.71% | 2.00% |
| Regeneron Pharmaceuticals, Inc. | 1.60% | 1.96% |
Source: SEC Form N-PORT
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
FAQ
What is the difference between JDOC and RSPH?
Which is cheaper, JDOC or RSPH?
Should I own both JDOC and RSPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.